Pharmaceuticals & Therapeutics

As its promising prostate cancer drug nears Phase 3, Convergent Therapeutics hires a new CPO to build the team for its next critical growth phase.

Enveric Biosciences raises $1.5M to advance its novel psychiatric drugs. Is this small cash infusion enough to propel its promising pipeline forward?

With a new $7.5M investment, Elysium Therapeutics is advancing SOOPR, a long-acting overdose rescue agent designed to combat the deadly fentanyl rebound.

Omeros begins sales of YARTEMLEA, the first and only approved therapy for TA-TMA, a fatal complication of stem cell transplants, shifting the paradigm.

Veteran leader Emma Rooth takes charge at PCCA UK, bringing a track record of transformation to the booming personalized medicine market.

Roche's CT-388 posts impressive Phase II results, positioning it as a powerful new rival to Zepbound and Wegovy in the booming obesity drug market.

LuskinOIC honors a pioneer of artificial joints with a new award, celebrating a legacy of innovation and propelling the next wave of orthopaedic discovery.

The acquisition strengthens the independent distributor's hold on the booming plasma therapy market, promising wider access to critical, complex medications.

As US organ donor registrations fall, Southern Legacy of Life achieves its second-best year, saving hundreds through strategic community engagement.

Neurocrine Biosciences begins a Phase 2 trial for a new tardive dyskinesia drug, aiming to build on its market dominance and offer new hope for patients.

Baird Medical partners with Stonewood Key Capital, using China's Hainan Free Trade Port to accelerate its global push for minimally invasive therapies.

With fresh funding, Primmune is advancing its unique TLR7 agonist, designed for efficacy without severe side effects, into a pivotal melanoma trial in Australia.

A first-in-class oral therapy targeting cellular metabolism has entered patient trials, offering new hope for a disease-modifying treatment for eczema.

Aja Health inks a deal with Greatway Financial to sell its MyCare Ally program and upgrades its GOeVisit platform for advanced virtual care services.

A new Canadian patent for a metformin-based eye drop could revolutionize treatment for degenerative eye diseases in both humans and their canine companions.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

With promising results in tough-to-treat colorectal cancer, a strong cash runway, and key alliances, Adagene is poised for a pivotal year.

As Embecta prepares its Q1 results, investors watch closely to see if its move beyond insulin can reverse recent revenue declines and reshape its future.

London's Ellipses Pharma in-licenses a novel B7H3 antibody-drug conjugate from Innolake, aiming to outmaneuver competitors with a unique payload.

With $287M in new funding, Corxel Pharmaceuticals aims to disrupt the obesity market with its oral GLP-1 drug, CX11, and a diverse cardiometabolic pipeline.